<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37283183</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1553-3840</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of complementary &amp; integrative medicine</Title><ISOAbbreviation>J Complement Integr Med</ISOAbbreviation></Journal><ArticleTitle>Icosapent ethyl (VASCEPA<sup>&#xae;</sup>) as treatment for post-acute sequelae of SARS CoV-2 (PASC) vaccine induced injury and infection.</ArticleTitle><Pagination><StartPage>662</StartPage><EndPage>664</EndPage><MedlinePgn>662-664</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1515/jcim-2023-0129</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">As the COVID-19 pandemic continues, a prolonged post-infectious syndrome or "long COVID" has been reported. This is a multi-organ post viral syndrome that persists well after infection. Currently, there is no available treatment. Emerging evidence credits this "long COVID" syndrome to ongoing inflammatory response following resolution of symptoms during infection. An omega-three fatty acid derivative used in the treatment of hypertriglyceridemia, Icosapent Ethyl (IPE, VASCEPA<sup>&#xae;</sup>/Epadel<sup>&#xae;</sup>), was previously shown to reduce cardiovascular risk, likely via immunomodulatory effects. This study aims to evaluate the effectiveness of Icosapent Ethyl.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Following previous publications in treatment of severe acute COVID-19, we analyze two case studies of adults treated with Icosapent Ethyl.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After experiencing the symptoms of Long Covid, both individuals analyzed across two case studies experiences a resolution of symptoms after treatment with Icosapent Ethyl.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">After review and analysis we conclude that Icosapent Ethyl may have been a determining factor in Long COVID symptom resolution and should be studied further.</AbstractText><CopyrightInformation>&#xa9; 2023 Walter de Gruyter GmbH, Berlin/Boston.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cruess</LastName><ForeName>Sean M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0003-0981-1873</Identifier><AffiliationInfo><Affiliation>Department of Biology, College of the Holy Cross, Worcester MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callahan</LastName><ForeName>Joseph Xavier</ForeName><Initials>JX</Initials><AffiliationInfo><Affiliation>Department of Chemistry, College of the Holy Cross, Worcester MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raso</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Chemistry, College of the Holy Cross, Worcester MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valencia</LastName><ForeName>Bryceida</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Chemistry, College of the Holy Cross, Worcester MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eskander</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Bon Secours Mercy, Portsmouth VA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Complement Integr Med</MedlineTA><NlmUniqueID>101313855</NlmUniqueID><ISSNLinking>1553-3840</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>6GC8A4PAYH</RegistryNumber><NameOfSubstance UI="C035276">eicosapentaenoic acid ethyl ester</NameOfSubstance></Chemical><Chemical><RegistryNumber>AAN7QOV9EA</RegistryNumber><NameOfSubstance UI="D015118">Eicosapentaenoic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015118" MajorTopicYN="N">Eicosapentaenoic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">icosopent ethyl</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">vaccine induced injury</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>7</Day><Hour>5</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37283183</ArticleId><ArticleId IdType="doi">10.1515/jcim-2023-0129</ArticleId><ArticleId IdType="pii">jcim-2023-0129</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian, A, Sehgal, K, Gupta, A, Madhavan, MV, McGroder, C, Stevens, JS, et al.. Post-acute COVID-19 syndrome. Nat Med 2021;27:1&#x2013;15. https://doi.org/10.1038/s41591-021-01283-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, M, Kleine-Weber, H, Schroeder, S, Kr&#xfc;ger, N, Herrler, T, Erichsen, S, et al.. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271&#x2013;80. https://doi.org/10.1016/j.cell.2020.02.052 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming, I, Timens, W, Bulthuis, M, Lely, A, Navis, G, van Goor, H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631&#x2013;7. https://doi.org/10.1002/path.1570 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1570</ArticleId></ArticleIdList></Reference><Reference><Citation>Go&#xeb;rtz, YMJ, Herck, MV, Delbressine, JM, Vaes, AW, Meys, R, Machado, FVC, et al.. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res 2020;6:1&#x2013;10. https://doi.org/10.1183/23120541.00542-2020 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00542-2020</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, C, Huang, L, Wang, Y, Li, X, Ren, L, Gu, X, et al.. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397:220&#x2013;32. https://doi.org/10.1016/s0140-6736(20)32656-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)32656-8</ArticleId></ArticleIdList></Reference><Reference><Citation>A possible mechanism behind brain fog [Internet]. NIH COVID-19 Research; 2022. Available from: https://covid19.nih.gov/news-and-stories/a-possible-mechanism-behind-brain-fog .</Citation></Reference><Reference><Citation>Conti, L, Berger, A, Ryan, L, Eskander, J. Icosapent ethyl (VASCEPA&#xae;) in the treatment of prolonged post-infectious COVID-19 symptoms [Internet]. www.cureus.com . Available from: https://www.cureus.com/publish/articles/92742-icosapent-ethyl-vascepa-in-the-treatment-of-prolonged-post-infectious-covid-19-symptoms/preview?token=K_GvFLfprFB2cyqJukEg&amp;utm_campaign=added_as_coauthor&amp;utm_medium=email&amp;utm_source=author_mailer# [Accessed 11 May 2023].</Citation></Reference><Reference><Citation>Bays, HE, Ballantyne, CM, Braeckman, RA, Stirtan, WG, Soni, PN. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs 2013;13:37&#x2013;46. https://doi.org/10.1007/s40256-012-0002-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40256-012-0002-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosy, AP, Malik, UI, Thomas, RC, Parikh, RV, Tan, TC, Goh, CH, et al.. Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE). Am Heart J 2021;235:54&#x2013;64.</Citation></Reference><Reference><Citation>Sherratt, SCR, Dawoud, H, Bhatt, DL, Malinski, T, Mason, RP. Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability. Prostagl Leukot Essent Fat Acids 2021;173:102337. https://doi.org/10.1016/j.plefa.2021.102337 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plefa.2021.102337</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt, DL, Steg, PG, Miller, M, Brinton, EA, Jacobson, TA, Ketchum, SB, et al.. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11&#x2013;22. https://doi.org/10.1056/nejmoa1812792 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1812792</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma, S, Bhatt, DL, Steg, PG, Miller, M, Brinton, EA, Jacobson, TA, et al.. Icosapent ethyl reduces ischemic events in patients with a history of previous coronary artery bypass grafting: REDUCE-IT CABG. Circulation 2021;144:1845&#x2013;55. https://doi.org/10.1161/circulationaha.121.056290 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.121.056290</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, M, Ballantyne, CM, Bays, HE, Granowitz, C, Doyle, RT, Juliano, RA, et al.. Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on atherogenic lipid/lipoprotein, apolipoprotein, and inflammatory parameters in patients with elevated high-sensitivity C-reactive protein (from the ANCHOR Study). Am J Cardiol 2019;124:696&#x2013;701. https://doi.org/10.1016/j.amjcard.2019.05.057 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2019.05.057</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinton, EA, Ballantyne, CM, Bays, HE, Kastelein, JJ, Braeckman, RA, Soni, PN. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200&#x2013;500&#xa0;mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol 2013;12:100. https://doi.org/10.1186/1475-2840-12-100 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1475-2840-12-100</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>